ALID (Allied) Notes Receivable: $0.00 Mil (As of Nov. 2024)


What is Allied Notes Receivable?

Allied ALID -99.80% Notes Receivable is $0.00 Mil as of Nov. 2024.

Allied's Notes Receivable for the quarter that ended in Nov. 2024 was $0.00 Mil.

Allied Notes Receivable Historical Data

* Premium members only.

The historical data trend for Allied's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied Notes Receivable Chart

Allied Annual Data
Trend Mar18 Mar19 Aug20 Aug21 Aug22 Aug23 Aug24
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Allied Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Allied Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Allied (ALID) has a Notes Receivable of $0.00 Mil as of Nov. 2024. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Allied and its competitors.
Is Allied's Notes Receivable too high?
Allied's current Notes Receivable is $0.00 Mil.
How does Allied's Notes Receivable compare to CBDY and PLSH?
Allied's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Allied and its competitors. Allied's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied stock overvalued right now?
Allied (ALID) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Allied (ALID), the current Notes Receivable is $0.00 Mil as of Nov. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allied Business Description

Address 460 Doyle Avenue, Suite 200, Kelowna, BC, CAN, V1Y OC2
Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments, which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised of sales of cannabis products.